Naimi, Rahim M <br/><br/>
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.  [electronic resource] 

 -  The lancet. Gastroenterology & hepatology  05 2019 
 - 354-363 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2468-1253 
<br/><br/><label>Standard No.: </label>10.1016/S2468-1253(19)30077-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abdominal Pain--chemically induced<br/>Aged<br/>Anorexia--chemically induced<br/>Colitis, Ulcerative--surgery<br/>Crohn Disease--surgery<br/>Cross-Over Studies<br/>Double-Blind Method<br/>Edema--chemically induced<br/>Enterostomy<br/>Fatigue--chemically induced<br/>Female<br/>Gastrointestinal Agents--therapeutic use<br/>Gastrointestinal Transit<br/>Glucagon-Like Peptide 2<br/>Humans<br/>Injection Site Reaction<br/>Intestinal Absorption<br/>Male<br/>Mesenteric Ischemia--surgery<br/>Mesenteric Vascular Occlusion--surgery<br/>Middle Aged<br/>Nausea--chemically induced<br/>Short Bowel Syndrome--drug therapy